Notes
The study was funded by Janssen Scientific Affairs, LLC.
Reference
Peterson ED, et al. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. American Heart Journal 212: 113-119, 20 Feb 2019. Available from: URL: http://doi.org/10.1016/j.ahj.2019.02.001
Rights and permissions
About this article
Cite this article
Rivaroxaban better value in morbidly obese patients with AF. PharmacoEcon Outcomes News 826, 28 (2019). https://doi.org/10.1007/s40274-019-5830-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5830-9